Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC
Condition(s):Prostate CancerLast Updated:July 15, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Prostate CancerLast Updated:July 15, 2022Recruiting
Condition(s):Metastatic Castration Resistant Prostate CancerLast Updated:November 3, 2020Completed
Condition(s):Androgen-Independent Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Prostate Cancer Recurrent; Androgen-Insensitive Prostatic Cance; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Immunotherapy; Immune Checkpoint Inhibitor; Inhibitory Checkpoint MoleculeLast Updated:March 26, 2024Recruiting
Condition(s):Prostate CancerLast Updated:May 17, 2017Completed
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:March 18, 2024Recruiting
Condition(s):Prostate CancerLast Updated:December 19, 2018Completed
Condition(s):Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents; Metastatic Prostate Adenocarcinoma; Progressive Disease; Prostate Carcinoma Metastatic in the Bone; Prostate Carcinoma Metastatic in the Soft Tissue; PSA Progression; Stage IVB Prostate Cancer AJCC v8; Testosterone Less Than 50 ng/dLLast Updated:April 27, 2022Active, not recruiting
Condition(s):Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate CancerLast Updated:March 5, 2024Active, not recruiting
Condition(s):Metastatic Castrate-resistant Prostate Cancer; Adenocarcinoma, ProstateLast Updated:April 23, 2021Completed
Condition(s):Prostate Cancer MetastaticLast Updated:May 1, 2017Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.